Please be advised that we cannot provide any medical information (about drugs, treatments, diagnostics, etc.). You are kindly requested to refer to your doctor or to Telefono Verde AIDS at the Istituto Superiore di Sanità (toll free number from Italy 800 861 061).
Our aim is fighting HIV/AIDS and associated syndromes by developing vaccines and new therapeutic approaches based on studies of the pathogenic mechanisms of HIV infection and progression. The NAC organization reflects the aim to put into effect a “translational” research.
The Tat-based phase II clinical trial “ISS T-002”.
Barbara Ensoli, Director of the National AIDS Center- ISS, was appointed among the new members of the European Research Council (European Research Council,...
As published today in PLoS ONE, by binding the Envelope protein present on virus particles, HIV Tat forms a new virus entry complex that favours the infection of cells present at the portals of virus entry (i.e. dendritic cells, macrophages). These cells represent also key HIV reservoirs that ensure the persistence of HIV in the host even under an "effective" antiretroviral treatment. By binding Env, Tat renders ineffective anti-Env antibodies at blocking virus entry in target cells. Thus, both anti-Tat and anti-Env antibodies are...
© - Istituto Superiore di Sanità Viale Regina Elena 299 - 00161 - Roma (I)
Partita I.V.A. 03657731000 - C.F. 80211730587 - Legal information